Schonfeld Strategic Advisors LLC Vincerx Pharma, Inc. Transaction History

Schonfeld Strategic Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.38 $321,845 - $672,950	-487,645 Reduced 81.05%	114,000 $115,000
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.9 $25,763 - $55,626	-29,277 Reduced 4.64%	601,645 $782,000
Q1 2023 May 15, 2023	BUY	$0.9 - $1.51 $51,908 - $87,090	57,676 Added 10.06%	630,922 $656,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.32 $59,264 - $122,232	92,600 Added 19.27%	573,246 $584,000
Q3 2022 Nov 14, 2022	BUY	$0.0 - $1.72 $0 - $322,061	187,245 Added 63.82%	480,646 $663,000
Q2 2022 Aug 15, 2022	BUY	$0.0 - $0.0 $0 - $0	28,524 Added 10.77%	293,401 $387,000
Q1 2022 May 16, 2022	SELL	$0.0 - $0.0 $0 - $0	-27,600 Reduced 9.44%	264,877 $1.06 Million
Q4 2021 Feb 14, 2022	BUY	$0.0 - $0.0 $0 - $0	21,655 Added 8.0%	292,477 $2.98 Million
Q3 2021 Nov 16, 2021	BUY	$0.0 - $0.0 $0 - $0	52,455 Added 24.02%	270,822 $4.38 Million
Q2 2021 Aug 16, 2021	BUY	$0.0 - $27.0 $0 - $175,500	6,500 Added 3.07%	218,367 $2.84 Million
Q1 2021 May 17, 2021	BUY	$22.6 - $31.0 $3.05 Million - $4.18 Million	134,930 Added 175.38%	211,867 $4.09 Million
Q4 2020 Feb 16, 2021	BUY	$12.85 - $19.95 $988,640 - $1.53 Million	76,937 New	76,937 $1.61 Million

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $4.03M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.